The US Buffett Stock

Teva Pharmaceuticals Reputation&Rating Reviews

Contents

1. The overview of “Teva Pharmaceuticals”
2. The detailed data of “Teva Pharmaceuticals”
3. The map of “Teva Pharmaceuticals”
4. The stock weekly chart of “Teva Pharmaceuticals”
5. The stock weekly trading radar of “Teva Pharmaceuticals”
6. The annual filings of “Teva Pharmaceuticals”
7. The stock price of “Teva Pharmaceuticals”
* Last update: July 20, 2021

The overview of “Teva Pharmaceuticals”

Teva Pharmaceutical Industries Ltd.“, founded in 1901, is a global pharmaceutical company with headquarters in Petah Tikva, Israel. It was given the current name on May 1, 1935. The company’s facilities are located in Israel, North America, South America, Europe, and Australia, and it specializes in generic drugs, business for pharmaceutical ingredients and proprietary pharmaceuticals. Also, it’s the eighteenth largest pharmaceutical company in the world.
 
In 2000, “Teva Pharmaceuticals” acquired Canada-based “Novopharm”, German generic “Ratiopharm” for 5 billion USD in August 2010, US-biopharmaceutical company “Cephalon” for 6.8 billion USD in May 2011, and Japanese generic drug company “Taiyo Pharmaceutical Industry” for 40 billion JPY in the same year. The company’s stocks are listed on not only the Tel Aviv Stock Exchange, but also the New York Stock Exchange (NYSE).

 
≫ Click here for returning

The detailed data of “Teva Pharmaceuticals”

Established date: 1901
Location: 5 Basel St, Petach Tikva 49131, Israel
Stock Exchange: NYSE(TEVA)
Listing date: 2012
Business details: Development and marketing of drugs(Biotechnlogy)
Official website:
https://www.teva.co.il/
https://www.tevapharm.com/

 
≫ Click here for returning

The map of “Teva Pharmaceuticals”

 
≫ Click here for returning

The stock weekly chart of “Teva Pharmaceuticals”



≫ Click here for returning

The stock weekly trading radar of “Teva Pharmaceuticals”


≫ Click here for returning

The annual filings of “Teva Pharmaceuticals”

* Date: Feb 10, 2021

* U.S. dollars in millions



Cutoff dateDecember 31, 2020December 31, 2019
Operating income(3,572)(443)
Net income attributable(3,990)(999)
Total current assets13,00513,464
Total current liabilities13,16413,674
Current ratio
(1.2 or more is the best)
0.990.98
Common stock and additional paid-in capital27,50027,368
Treasury stock(4,128)(4,128)
Retained earning, Accumulated deficit(10,946)(6,956)
Total stockholders' equity11,06115,063
Total equity and liabilities50,64057,470
Equity ratio
(20% or more is better)
(50% or more is the best)
21.84%26.21%
Cash flows from operating activities1,216748
Cash flows from investing activities8631,355
Cash flows from financing activities(1,885)(1,926)
Free cash flow2,0792,103

 
≫ Click here for returning

The stock price of “Teva Pharmaceuticals”

* Comment

Loss from operations expanded and Accumulated deficit increased.

Equity ratio declined, but it's not bad situation because of more than 20%.

As much as possible, it might be better that Current ratio are raised in order to aim Retained earning.

The stock price of "Teva Pharmaceuticals" in 2021 might tend to be stagnant as well as 2020.



Term year20212020
Entity min stock price in monthly chartN/Aapprox 8.6 (Apr)
Entity max stock price in monthly chartN/Aapprox 12.6 (Jun)
Stock price increase ratio
(50% or more is the best)
N/A46.5%

 
≫ Click here for returning
 

Related post

  1. Restoration Hardware Reputation…

  2. Globe Life Reputation&Rating R…

  3. Rafael Holdings Reputation&Rat…

  4. Marsh&McLennan Reputation&…

  5. T-Mobile US Reputation&Rating …

  6. AbbVie Reputation&Rating Revie…

Major global markets

PAGE TOP